Allergan

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Bank of Nova Scotia

Duke Energy

Northrop Grumman

Prudential

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

6 Stocks With Low Price-Sales Ratios

AbbVie

Amgen

Biogen

Bristol-Myers

Celgene

Gilead Sciences

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Will Patent Woes Boost Pharma Stock Megamergers Further?

Eli Lilly

Spark Therapeutics

Pfizer

Roche Holding AG

Vertex Pharmaceuticals

Biotech companies exploded with "megadeals" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
The post Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019 appeared first on Investor's Business Daily.

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

The AbbVie Allergan deal is being criticized for not being strategic and being more of the same.

AbbVie Allergan, A Boring But Prudent Deal

Merck

After two mega-mergers, Bristol-Myers/Celgene and AbbVie/Allergan, in first half of 2019, it remains to be seen if more such deals are in store for the second half.

Will the Pharma Space Witness More Mega-Merger Deals in 2H?

McKesson

Walgreens

My investment management firm has a large position in the health care sector, and with AbbVie’s bid for Allergan earlier this week, it’s timely to review why we bought into this sector.

Here's Why Drug-Distribution and Pharmacy Stocks Are Bargains Now

AbbVie's Allergan deal isn't as bad as some might think.

4 Reasons to Buy AbbVie Now That It's Acquiring Allergan

AbbVie has announced a plan to acquire Allergan for more than $60 billion. This transaction has been fully financed and is expected to close in early-2020.

AbbVie And Allergan - Take Advantage Of AbbVie's Share Price Drop

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Is Allergan a Good Deal for AbbVie?

Analysts offered mixed views Wednesday on AbbVie's $63 billion takeover of Botox-maker Allergan — a deal meant to lessen the pharmaceutical company's dependence on arthritis drug Humira.
The post AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan appeared first on Investor's Business Daily.

AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan

AbbVie's buying Allergan for around $63 billion and shareholders from both companies are not on board.

Here's Why Nobody's Happy About This $63 Billion Buyout

AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.

AbbVie deal may conclude a tumultuous 4 years for Botox-maker Allergan

AbbVie became the latest player to pursue a pharma megadeal.

AbbVie wants to acquire Allergan in the latest pharma megadeal

AbbVie (ABBV) is on the hunt for their next big revenue driver as their patent for the world???s top-selling drug, Humira, is nearing its end.

AbbVie + Allergan: Where Are The Synergies?

BlackBerry

FedEx

Microsoft

AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.

5 Top Stock Trades for Wednesday June 26

AbbVie is buying Botox-maker Allergan in a $63 billion deal, the pharma giant announced Tuesday — sending Allergan stock rocketing. The deal comes as AbbVie's Humira faces biosimilars.

Pharma Buying Spree Continues As AbbVie Takes Out Allergan For $63 Billion

Allergan agrees to a deal that values the stock at $188 per share for a 45% premium.

Allergan: Stay For The AbbVie Shares

News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday with plans for the former company to acquire the latter.

AbbVie-Allergan Deal: AGN Stock Soars on $63 Billion Buyout

Stock Market News: AbbVie Bets Big

Investors are cheering Allergan and jeering AbbVie after the announcement of a major acquisition.

Why AbbVie Stock Is Sinking and Allergan Is Soaring Today

On Tuesday The Wall Street Journal reported that AbbVie Inc. (NYSE:ABBV) is a whisper away from the successful completion of a $188.24 share bid for the acquisition of Allergan Plc (NYSE:AGN) for a total consideration of over $60 billion.

AbbVie Buys Allergan for Over $60 Billion

AbbVie Is Buying Botox-Maker Allergan In A $63 Billion Takeover

Drugmaker AbbVie said on Tuesday it would buy Botox-maker Allergan for about $63 billion, grabbing control of by far the biggest name in medical aesthetics to help reduce its reliance on blockbuster arthritis treatment Humira. Allergan chief executive officer Brent Saunders put together the current version of the company through a series of deals to.

AbbVie to buy Botox-maker Allergan in $63 billion deal

Overpaying for Allergan would be a serious misstep.

AbbVie’s $63 Billion Mistake

Advanced Micro Devices

Zoom Video

Growth stocks AMD, Shopify, Zoom Video, Ulta and Veeva raised stock market rally concerns. AbbVie will buy Allergan for $63 billion.

News for Allergan Stock (AGN)